Tweet
Our core has been using the Fluidigm C1 Single Cell Analyzer for generating cDNA for Illumina seq with the NEXTera kits. Do any other cores offer this service? I was trying to establish a fair price and looking to see what kind of issues others have encountered? So far, the biggest problem we have encountered is capture inefficiency on the C1 chip. However, with certain cultured cells we have gotten great capture. We normally run into problems with primary cells dying in the chip. Anyone have any troubleshooting advice?
-
-
I wish I had advice but we are having the same issue.
The only thing we have discovered is that even though they tell you that you can run the capture up to 3X to increase the capture number on the small cells, it isn't worth the time and effort-you might get 2 more. -
Kwaraska-
Thanks for the reply. I know this is a relatively new instrument, so we are trying to work out all the kinks. Please keep me updated if you have any new tips or tricks and I will do the same.
Comment
-
We're interested in trying single-cell RNA seq as well. Does anyone know of a core or service provider currently offering this as a service?
Can those of you who have the fluidigm system in hand give any info as to the price? In this thread, $23/sample was mentioned as the library cost. Does that seem right?
Thanks for any help or additional thoughts. I'm very interested to see whether this is feasible for us!Comment
-
You mention you are in Boston.
The BPF at Harvard Medical School has a C1.
Here is a link to the website www.genome.med.harvard.eduComment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...Today, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment